Capecitabine (X) and Irinotecan (I), in a biweekly schedule, for patients (Pts) with advanced/metastasic colorectal cancer (MCRC): interim analysis of a phase II study

被引：0
|
作者：
Garcia-Alfonso, Pilar [1 ]
Gonzalez, M. C. [2 ]
Gonzalez, E. [3 ]
Molina, M. [4 ]
Monoz, A. [1 ]
Abad, G. [1 ]
Garcia, S. [1 ]
Lopez, P. [2 ]
Belon, J. [3 ]
Perez-Manga, G. [1 ]
机构：
[1] Hosp Gregorio Maranon, Madrid, Spain
[2] Hosp Mostoles, Mostoles, Spain
[3] HU Virgen Nieves, Granada, Spain
[4] H Gen Segovia, Oncol, Segovia, Spain
来源：
ANNALS OF ONCOLOGY | 2004年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：89 / 89
页数：1
相关论文
共 50 条
  • [1] A phase II trial of capecitabine (X) and irinotecan (I), in a biweekly schedule, for patients (Pts) with advanced/metastatic colorectal cancer (MCRC).
    Garcia-Alfonso, P
    Gonzalez-Arenas, C
    Gonzalez-Flores, E
    Molina, M
    Muñoz, A
    Abad, G
    Garcia-Adrian, S
    Lopez, P
    Belon, J
    Perez-Manga, G
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 290S - 290S
  • [2] A phase II trial of Capecitabine (X) and Irinotecan (I) in a biweekly schedule in patients with untreated advanced colorectal cancer (ACRC)
    Garcia-Alfonso, P.
    Perez MAnga, G.
    Gonzalez, M. C.
    Lopez, P.
    Gonzalez, E.
    Belon, J.
    Molina, M.
    Pachon, V.
    Iglesias, L.
    Siso, I.
    EJC SUPPLEMENTS, 2005, 3 (02): : 181 - 181
  • [3] A phase II trial of a biweekly schedule of capecitabine (X) plus irinotecan (1) as first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC).
    Garcia-Alfonso, P
    Perez-Manga, G
    Gonzalez, MC
    Lopez, P
    Gonzalez, E
    Belon, J
    Molina, M
    Pachon, V
    Iglesias, L
    Siso, I
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 256S - 256S
  • [4] A phase II trial of capecitabine plus irinotecan (XELIRI) in a biweekly schedule in patients with untreated metastatic colorectal cancer (MCRC)
    Garcia Alfonso, Pilar
    Perez-Manga, Gumersindo
    Gonzalez, M. C.
    Lopez, P.
    Gonzalez, E.
    Belon, J.
    Molina, M.
    Pachon, V.
    Iglesias, L.
    Munoz, V.
    ANNALS OF ONCOLOGY, 2006, 17 : 119 - 120
  • [5] A phase I/II study of capecitabine (X), irinotecan (I) and oxaliplatin (O) as first-line therapy in patients (PTS) with advanced or metastatic colorectal cancer (MCRC)
    Maroun, Jean A.
    Jonker, Derek
    Goel, Rakesh
    Cripps, Christine
    Lister, Diane
    Chiritescu, Gabriela
    ANNALS OF ONCOLOGY, 2006, 17 : 119 - 119
  • [6] Capecitabine (X), irinotecan (I) and bevacizumab (A) as first-line therapy for patients (PTS) with metastatic colorectal cancer (MCRC): Preliminary phase II study results
    Semir, Beslija
    Maja, Banjin
    Nadja, Paraganlija
    Timur, Ceric
    Anes, Pasic
    Berisa, Salkic
    Anes, Sosevic
    Nermina, Obralic
    ANNALS OF ONCOLOGY, 2006, 17 : 127 - 127
  • [7] A PHASE II STUDY OF CAPECITABINE, IRINOTECAN, AND BEVACIZUMAB (XELIRI-A) IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (MCRC)
    Chen, E.
    Welch, S.
    Kryzanowska, M.
    Mackay, H.
    Knox, J.
    Feld, R.
    Petronis, J.
    Blatter, C.
    Wang, L.
    Moore, M.
    ANNALS OF ONCOLOGY, 2009, 20 : 36 - 37
  • [8] A phase II study of capecitabine, irinotecan, and bevacizumab (XELIRI-A) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC)
    Chen, E. X.
    Welch, S.
    Krzyzanowska, M.
    MacKay, H.
    Knox, J.
    Feld, R.
    Petronis, J.
    Blatter, C.
    Wang, L.
    Moore, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] Phase II study of oxaliplatin, capecitabine, and irinotecan (OCI) in patients (pts) with previously untreated advanced colorectal cancer
    Pavia, OA
    Cangiano, J
    Crisostomo, R
    Caceres, W
    Barranco, E
    Wright, M
    Antonia, T
    Antonia, S
    Sullivan, D
    Garrett, C
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 307S - 307S
  • [10] Phase II study of celecoxib, irinotecan, and capecitabine in patients with advanced colorectal cancer
    El-Rayes B
    Shields, A.
    Zalupski, M.
    Bekaii-Saab, T.
    Heilbrun, L.
    Vaishampayan, U.
    Manza, S.
    ANNALS OF ONCOLOGY, 2006, 17 : 70 - 70
12345